ArticleOncology letters2025

FBXL22, a circadian-regulated immune biomarker with pan-cancer prognostic value and therapeutic potential in prostate cancer.

Jin Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.